169 related articles for article (PubMed ID: 27273997)
1. [New insight in pathogenesis of podocyte disfunction in minimal change disease].
Liu S; Chen J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 45(2):214-8. PubMed ID: 27273997
[TBL] [Abstract][Full Text] [Related]
2. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
Agrawal V; Prasad N; Jain M; Pandey R
Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice.
Ishimoto T; Shimada M; Gabriela G; Kosugi T; Sato W; Lee PY; Lanaspa MA; Rivard C; Maruyama S; Garin EH; Johnson RJ
Nephrol Dial Transplant; 2013 Jun; 28(6):1439-46. PubMed ID: 23262434
[TBL] [Abstract][Full Text] [Related]
4. New insights into human minimal change disease: lessons from animal models.
Chugh SS; Clement LC; Macé C
Am J Kidney Dis; 2012 Feb; 59(2):284-92. PubMed ID: 21974967
[TBL] [Abstract][Full Text] [Related]
5. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease.
Li JS; Chen X; Peng L; Wei SY; Zhao SL; Diao TT; He YX; Liu F; Wei QJ; Zhang QF; Li B
PLoS One; 2015; 10(9):e0137049. PubMed ID: 26352670
[TBL] [Abstract][Full Text] [Related]
6. Minimal change disease: a "two-hit" podocyte immune disorder?
Shimada M; Araya C; Rivard C; Ishimoto T; Johnson RJ; Garin EH
Pediatr Nephrol; 2011 Apr; 26(4):645-9. PubMed ID: 21052729
[TBL] [Abstract][Full Text] [Related]
7. "Idiopathic" minimal change nephrotic syndrome: a podocyte mystery nears the end.
Chugh SS; Clement LC
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F685-F694. PubMed ID: 37795536
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
Shen X; Zhang Y; Lin C; Weng C; Wang Y; Feng S; Wang C; Shao X; Lin W; Li B; Wang H; Chen J; Jiang H
J Pathol; 2020 Nov; 252(3):227-238. PubMed ID: 32686149
[TBL] [Abstract][Full Text] [Related]
9. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G; Venkatareddy M; Verma R; Segarra A; Cleuren AC; Martínez-Ramos A; Johnson RJ; Garg P
Pediatr Nephrol; 2020 Oct; 35(10):1887-1896. PubMed ID: 32399663
[TBL] [Abstract][Full Text] [Related]
10. β1-Integrin blockade prevents podocyte injury in experimental models of minimal change disease.
Cara-Fuentes G; Verma R; Venkatareddy M; Bauer C; Piani F; Aksoy ST; Vazzalwar N; Garcia GE; Banks M; Ordoñez FA; de Lucas-Collantes C; Bjornstad P; González Rodríguez JD; Johnson RJ; Garg P
Nefrologia (Engl Ed); 2024; 44(1):90-99. PubMed ID: 37150673
[TBL] [Abstract][Full Text] [Related]
11. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.
Clement LC; Avila-Casado C; Macé C; Soria E; Bakker WW; Kersten S; Chugh SS
Nat Med; 2011 Jan; 17(1):117-22. PubMed ID: 21151138
[TBL] [Abstract][Full Text] [Related]
12. Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice.
Yamashita M; Yoshida T; Suzuki S; Homma K; Hayashi M
Clin Exp Nephrol; 2017 Feb; 21(1):16-26. PubMed ID: 27089875
[TBL] [Abstract][Full Text] [Related]
13. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.
Cara-Fuentes G; Clapp WL; Johnson RJ; Garin EH
Pediatr Nephrol; 2016 Dec; 31(12):2179-2189. PubMed ID: 27384691
[TBL] [Abstract][Full Text] [Related]
15. Synaptopodin expression in idiopathic nephrotic syndrome of childhood.
Srivastava T; Garola RE; Whiting JM; Alon US
Kidney Int; 2001 Jan; 59(1):118-25. PubMed ID: 11135064
[TBL] [Abstract][Full Text] [Related]
16. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
Teh YM; Lim SK; Jusoh N; Osman K; Mualif SA
Biomed Res Int; 2021; 2021():6671552. PubMed ID: 33506028
[TBL] [Abstract][Full Text] [Related]
17. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.
Lai KW; Wei CL; Tan LK; Tan PH; Chiang GS; Lee CG; Jordan SC; Yap HK
J Am Soc Nephrol; 2007 May; 18(5):1476-85. PubMed ID: 17429054
[TBL] [Abstract][Full Text] [Related]
19. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.
Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li KT; Szeto CC
Ren Fail; 2010 Jan; 32(3):372-9. PubMed ID: 20370455
[TBL] [Abstract][Full Text] [Related]
20. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2007; 27(6):710-5. PubMed ID: 18336100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
